Meeder Asset Management’s Arena Pharmaceuticals Inc ARNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-4,513
Closed -$339K 2370
2020
Q3
$339K Buy
4,513
+2,221
+97% +$148K 0.02% 474
2020
Q2
$144K Buy
2,292
+912
+66% +$50.2K 0.01% 673
2020
Q1
$57K Sell
1,380
-8,300
-86% -$381K ﹤0.01% 874
2019
Q4
$439K Buy
9,680
+3,231
+50% +$153K 0.03% 424
2019
Q3
$295K Buy
6,449
+1,198
+23% +$67.3K 0.02% 512
2019
Q2
$307K Buy
5,251
+2,018
+62% +$104K 0.02% 492
2019
Q1
$145K Sell
3,233
-3,158
-49% -$145K 0.01% 615
2018
Q4
$249K Buy
+6,391
New +$251K 0.02% 459
2018
Q3
Sell
-2,684
Closed -$117K 1745
2018
Q2
$117K Buy
2,684
+1,913
+248% +$82.2K 0.01% 596
2018
Q1
$30K Buy
771
+319
+71% +$12.4K ﹤0.01% 789
2017
Q4
$15K Buy
452
+125
+38% +$3.56K ﹤0.01% 1031
2017
Q3
$8K Sell
327
-237
-42% -$5.44K ﹤0.01% 1144
2017
Q2
$10K Buy
564
+98
+21% +$1.34K ﹤0.01% 1004
2017
Q1
$7K Buy
466
+420
+913% +$6.22K ﹤0.01% 973
2016
Q4
$1K Buy
+46
New +$712 ﹤0.01% 968

Other funds holding ARNA

Meeder Asset Management's ARNA Position: Q4 2020 in Review

Meeder Asset Management sold out of Arena Pharmaceuticals Inc (ARNA) in Q4 2020, closing a stake of 4,513 shares — an estimated $339K sold.

Meeder Asset Management first reported a position in ARNA in Q4 2016 and held it in 15 quarters. The position peaked at $439K in Q4 2019. 254 funds tracked by Wall St. Rank hold ARNA as of Q4 2020.

  • Meeder Asset Management reported no remaining Arena Pharmaceuticals Inc position as of Q4 2020 after selling out during the quarter.
  • Meeder Asset Management sold 4,513 Arena Pharmaceuticals Inc shares in Q4 2020, an estimated $339K.
  • Meeder Asset Management first reported a position in Arena Pharmaceuticals Inc in Q4 2016 and held it in 15 quarters.
  • Meeder Asset Management's Arena Pharmaceuticals Inc position peaked at $439K in Q4 2019.
  • 254 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q4 2020.

Based on Meeder Asset Management's 13F filing for Q4 2020, filed 9 Feb 2021.